ArticleJournal of gastrointestinal oncology2026
Colon cancer cachexia remodels gut microbiota and metabolite profiles in a murine model.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Association Between Gut Microbiome and Cachexia in Colorectal Cancer: A Systematic Review.Cancers · 2026Review
- C26 and CT26 colorectal cancer models exhibit divergent cachexia phenotypes, intramuscular inflammation, and protein turnover signaling.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer cachexia is a multifactorial syndrome involving involuntary weight loss, muscle atrophy, and systemic inflammation, contributing significantly to mortality in advanced cancers. Although gut microbiota dysbiosis has been implicated in metabolic and inflammatory disturbances relevant to cachexia, the functional metabolic consequences remain poorly understood. Using a murine model of colon carcinoma 26 (C26)-induced cachexia, we integrated metagenomic sequencing and non-targeted metabolomics to delineate cachexia-specific microbial and metabolic alterations compared to non-cachexia tumor-bearing and healthy controls. Methods: To investigate colon cancer cachexia-induced remodeling of the gut ecosystem, we established mouse models using cachexia-inducing and non-cachexia-inducing colon carcinoma 26 cells. Food intake, body weight, muscle and fat weight were monitored. Cecal content was collected for metagenomic sequencing and non-targeted metabolome analysis. Results: Colon cancer cachexia models were successfully established as evidenced by reduced food intake, decreased body weight, and loss of muscle and fat mass. Metagenomic sequencing revealed decreased microbial diversity and distinct structural separation in colon cancer cachexia mice, with enriched genera including Conclusions: Colon cancer cachexia remodeled the gut microbiota and metabolite landscape in a murine model. These findings suggested specific bacterial taxa and metabolites as potential biomarkers and therapeutic targets, offering new directions for the prevention and treatment of cancer cachexia. This study reveals distinct taxonomic and functional shifts in the gut microbiota alongside associated metabolic disruptions, offering new insights into cachexia pathophysiology and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.